Clinical Trial Update: Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial evaluates the safety, tolerability, and preliminary efficacy of intravenously delivered allogeneic placental mesenchymal cells to prevent ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• Allogeneic placental mesenchymal cells (placental mesenchymal cells)

Snippet

Sponsor: Kelifarma | Conditions: Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING